Vaccine value profile for enterotoxigenic Escherichia coli (ETEC)

[1]  D. Sack,et al.  Evaluation of a simple, rapid and field-adapted diagnostic assay for enterotoxigenic E. coli and Shigella , 2022, PLoS neglected tropical diseases.

[2]  B. Giersing,et al.  What Drives the Value of a Shigella Vaccine? , 2022, Vaccines.

[3]  S. Harutyunyan,et al.  Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial , 2022, Vaccines.

[4]  S. Chakraborty,et al.  Development of a simple, rapid, and sensitive diagnostic assay for enterotoxigenic E. coli and Shigella spp applicable to endemic countries , 2022, PLoS neglected tropical diseases.

[5]  R. Laxminarayan.  The overlooked pandemic of antimicrobial resistance , 2022, The Lancet.

[6]  G. Kang,et al.  World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens. , 2021, Vaccine.

[7]  Q. Bassat,et al.  Pathogens Associated With Linear Growth Faltering in Children With Diarrhea and Impact of Antibiotic Treatment: The Global Enteric Multicenter Study , 2021, The Journal of infectious diseases.

[8]  D. Sack,et al.  Characterization of Enteric Disease in Children by Use of a Low-Cost Specimen Preservation Method , 2021, Journal of clinical microbiology.

[9]  J. Fleckenstein.  Confronting Challenges to Enterotoxigenic Escherichia coli Vaccine Development , 2021, Frontiers in Tropical Diseases.

[10]  M. Prouty,et al.  Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli , 2021, Vaccine.

[11]  R. Choy,et al.  Vaccines for Protecting Infants from Bacterial Causes of Diarrheal Disease , 2021, Microorganisms.

[12]  G. Kang,et al.  Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access , 2021, Vaccine.

[13]  R. Guerrant,et al.  Modeling Enteropathy or Diarrhea with the Top Bacterial and Protozoal Pathogens: Differential Determinants of Outcomes , 2021, ACS infectious diseases.

[14]  A. Kantele,et al.  Extended-spectrum beta-lactamase-producing strains among diarrhoeagenic Escherichia coli—prospective traveller study with literature review , 2021, Journal of travel medicine.

[15]  J. Corander,et al.  Dynamics of intestinal multidrug-resistant bacteria colonisation contracted by visitors to a high-endemic setting: a prospective, daily, real-time sampling study , 2021, The Lancet. Microbe.

[16]  R. Rappuoli,et al.  The role of vaccines in combatting antimicrobial resistance , 2021, Nature Reviews Microbiology.

[17]  G. Kang,et al.  Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Sack,et al.  Intestinal and systemic inflammation induced by symptomatic and asymptomatic enterotoxigenic E. coli infection and impact on intestinal colonization and ETEC specific immune responses in an experimental human challenge model , 2021, Gut microbes.

[19]  J. Heinrichs,et al.  Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model. , 2020, Vaccine.

[20]  S. Harutyunyan,et al.  Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC , 2020, Vaccines.

[21]  Tanawan Samleerat Carraway,et al.  Rapid visual detection of hepatitis C virus using a reverse transcription loop-mediated isothermal amplification assay , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[22]  C. Drakeley,et al.  Prevalence and diversity of enteric pathogens among cholera treatment centre patients with acute diarrhea in Uvira, Democratic Republic of Congo , 2020, BMC Infectious Diseases.

[23]  D. Tribble,et al.  A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G. , 2020, Vaccine.

[24]  R. Choy,et al.  Validation of the Micronutrient and Environmental Enteric Dysfunction Assessment Tool and evaluation of biomarker risk factors for growth faltering and vaccine failure in young Malian children , 2020, PLoS neglected tropical diseases.

[25]  A. Pollard,et al.  Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies , 2020, Biologicals : journal of the International Association of Biological Standardization.

[26]  J. Lewnard,et al.  Incidence and etiology of clinically-attended, antibiotic-treated diarrhea among children under five years of age in low- and middle-income countries: Evidence from the Global Enteric Multicenter Study , 2020, medRxiv.

[27]  V. Chigor,et al.  Treated wastewater used in fresh produce irrigation in Nsukka, Southeast Nigeria is a reservoir of enterotoxigenic and multidrug-resistant Escherichia coli , 2020, Heliyon.

[28]  R. Guerrant,et al.  A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice , 2020, npj Vaccines.

[29]  R. Gilman,et al.  Application of a cost-effectiveness analysis of pathogen-specific vaccines against gastroenteritis to a military population in a developing country setting. , 2020, Vaccine.

[30]  Q. Bassat,et al.  Diarrhoeal disease and subsequent risk of death in infants and children residing in low-income and middle-income countries: analysis of the GEMS case-control study and 12-month GEMS-1A follow-on study , 2019, The Lancet. Global health.

[31]  I. Feavers,et al.  Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  F. Qadri,et al.  Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial , 2019, The Lancet. Infectious diseases.

[33]  K. Bagamian,et al.  Heterogeneity in enterotoxigenic Escherichia coli and shigella infections in children under 5 years of age from 11 African countries: a subnational approach quantifying risk, mortality, morbidity, and stunting , 2019, The Lancet. Global health.

[34]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[35]  Peter G. Smith,et al.  Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy , 2019, Vaccine.

[36]  J. Vekemans,et al.  Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance’s 2018 Vaccine Investment Strategy: report from an expert survey , 2019, F1000Research.

[37]  T. Wierzba,et al.  Heterogeneity in potential impact and cost-effectiveness of ETEC and Shigella vaccination in four sub-Saharan African countries , 2019, Vaccine: X.

[38]  M. Klempner,et al.  Oral administration of an anti-CfaE secretory IgA antibody protects against Enterotoxigenic Escherichia coli diarrheal disease in a non-human primate model , 2019, bioRxiv.

[39]  T. Wierzba.  Implications and measurement of herd protection (indirect effects) for enteric vaccine development. , 2019, Vaccine.

[40]  C. Porter,et al.  Clinical endpoints for efficacy studies. , 2019, Vaccine.

[41]  R. Baral,et al.  Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low- and lower middle-income countries , 2019, Vaccine: X.

[42]  D. Sack,et al.  Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge , 2019, Vaccine.

[43]  J. Fleckenstein,et al.  Enterotoxigenic Escherichia coli Infections , 2019, Current Infectious Disease Reports.

[44]  K. Bagamian,et al.  Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis , 2019, The Lancet. Global health.

[45]  N. Praet,et al.  Introducing new vaccines in low- and middle-income countries: challenges and approaches , 2019, Expert review of vaccines.

[46]  M. Riddle,et al.  Travelers’ diarrhea: update on the incidence, etiology and risk in military and similar populations – 1990-2005 versus 2005–2015, does a decade make a difference? , 2019, Tropical Diseases, Travel Medicine and Vaccines.

[47]  E. Brindle,et al.  Measurement of micronutrient deficiency associated biomarkers in dried blood spots using a multiplexed immunoarray , 2019, PloS one.

[48]  E. Hall,et al.  Establishment, Validation, and Application of a New World Primate Model of Enterotoxigenic Escherichia coli Disease for Vaccine Development , 2018, Infection and Immunity.

[49]  P. Dull,et al.  Combination vaccine strategies to prevent enteric infections. , 2017, Vaccine.

[50]  N. Grassly,et al.  Causes of impaired oral vaccine efficacy in developing countries , 2017, Future microbiology.

[51]  A. Svennerholm,et al.  Cross-reactivity and avidity of antibody responses induced in humans by the oral inactivated multivalent enterotoxigenicEscherichia coli (ETEC) vaccine ETVAX. , 2017, Vaccine.

[52]  U. Parashar,et al.  Correlates of protection for enteric vaccines. , 2017, Vaccine.

[53]  Mark A. Miller,et al.  Causal Pathways from Enteropathogens to Environmental Enteropathy: Findings from the MAL-ED Birth Cohort Study , 2017, EBioMedicine.

[54]  M. Riddle,et al.  Chronic Health Consequences of Acute Enteric Infections in the Developed World , 2016 .

[55]  A. L. Bourgeois,et al.  Status of vaccine research and development for enterotoxigenic Escherichia coli. , 2016, Vaccine.

[56]  Mark A. Miller,et al.  Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). , 2015, The Lancet. Global health.

[57]  R. Walker,et al.  Recommendations regarding the development of combined enterotoxigenic Eschericha coli and Shigella vaccines for infants. , 2015, Vaccine.

[58]  R. Walker,et al.  An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children. , 2015, Vaccine.

[59]  J. Corander,et al.  Identification of enterotoxigenic Escherichia coli (ETEC) clades with long-term global distribution , 2014, Nature Genetics.

[60]  R. Frenck,et al.  Diarrhea Burden Due to Natural Infection with Enterotoxigenic Escherichia coli in a Birth Cohort in a Rural Egyptian Community , 2014, Journal of Clinical Microbiology.

[61]  D. Sack,et al.  Estimating Diarrheal Illness and Deaths Attributable to Shigellae and Enterotoxigenic Escherichia coli among Older Children, Adolescents, and Adults in South Asia and Africa , 2014, PLoS neglected tropical diseases.

[62]  Inacio Mandomando,et al.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study , 2013, The Lancet.

[63]  D. Durrheim,et al.  New vaccine introductions: assessing the impact and the opportunities for immunization and health systems strengthening. , 2013, Vaccine.

[64]  Sean R. Moore,et al.  The impoverished gut—a triple burden of diarrhoea, stunting and chronic disease , 2013, Nature Reviews Gastroenterology &Hepatology.

[65]  D. Sack,et al.  Refinement of a Human Challenge Model for Evaluation of Enterotoxigenic Escherichia coli Vaccines , 2011, Clinical and Vaccine Immunology.

[66]  D. Tribble,et al.  A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). , 2011, Vaccine.

[67]  D. Sack,et al.  Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19. , 2011, The Journal of infectious diseases.

[68]  T. Hooper,et al.  Development of a travelers' diarrhea vaccine for the military: how much is an ounce of prevention really worth? , 2008, Vaccine.

[69]  F. Qadri,et al.  Disease Burden Due to Enterotoxigenic Escherichia coli in the First 2 Years of Life in an Urban Community in Bangladesh , 2007, Infection and Immunity.

[70]  D. Sack,et al.  Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. , 2007, Vaccine.

[71]  M. Wolf,et al.  Immune Response, Ciprofloxacin Activity, and Gender Differences after Human Experimental Challenge by Two Strains of Enterotoxigenic Escherichia coli , 2006, Infection and Immunity.

[72]  D. Tribble,et al.  Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. , 2006, The American journal of tropical medicine and hygiene.

[73]  M. Burkitt,et al.  Identification of a Two-Partner Secretion Locus of Enterotoxigenic Escherichia coli , 2006, Infection and Immunity.

[74]  R. Steffen,et al.  Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. , 2006, Journal of travel medicine.

[75]  A. Faruque,et al.  Enterotoxigenic Escherichia coli and Vibrio cholerae Diarrhea, Bangladesh, 2004 , 2005, Emerging infectious diseases.

[76]  J. Clemens,et al.  Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. , 2005, Vaccine.

[77]  T. Ahmed,et al.  Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol , 1999, The Lancet.

[78]  D. Nalin,et al.  Immunity to Enterotoxigenic Escherichia coli , 1979, Infection and immunity.

[79]  B. Jönsson,et al.  Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea. , 2009, Journal of travel medicine.